COMPANY

ONL Therapeutics

Company-reported stage: Phase 2 · source · Oct 12, 2026

Location: Ann Arbor, MI · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Rhegmatogenous Retinal Detachment - Macula Off Geographic Atrophy Age - Related Macular Degeneration Open Angle Glaucoma ONL1204

Raises and deals from press releases

Raise Series D · $65M · announced Sep 13, 2024 Company release ↗
Source quote
- Sep 13, 2024 · Company release ↗
  “ONL Therapeutics Closes $65 Million in Oversubscribed Series D Financing Funds will advance the development of ONL1204 Ophthalmic Solution with the initiation of a Phase 2 global study for the treatment of geographic atrophy (GA) associated with dry age-related macular degeneration (AMD) ANN”

Raises announced in these releases: $65M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Oct 28, 2025 Trial start Phase 2: Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD source ↗
Sep 13, 2024 Raise Series D · $65M source ↗
Apr 4, 2023 Trial start 2: A Phase 2 Study to Assess the Safety and Efficacy of Intravitreal ONL1204 Ophthalmic Solution in Subjects With Mac-off Retinal Detachment source ↗
May 2, 2022 Trial start 1: A Phase 1b Study of ONL1204 Ophthalmic Solution in Patients with Progressing Open Angle Glaucoma source ↗
Jul 8, 2021 Trial start Phase 1: ONL1204 Ophthalmic Solution in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration source ↗
Oct 21, 2019 Trial start Phase 1: A Study to Evaluate the Safety and Tolerability of ONL1204 in Patients With Macula-off, Rhegmatogenous Retinal Detachment source ↗

2028-11 (ESTIMATED) · Phase 2 · Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD · NCT06659445

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT06659445	Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD	Phase 2	Recruiting	Oct 28, 2025	2028-11 (estimated)
NCT04744662	ONL1204 Ophthalmic Solution in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration	Phase 1	Completed	Jul 8, 2021	Feb 29, 2024 (actual)
NCT05160805	A Phase 1b Study of ONL1204 Ophthalmic Solution in Patients with Progressing Open Angle Glaucoma	1	Completed	May 2, 2022	Apr 9, 2024 (actual)
NCT03780972	A Study to Evaluate the Safety and Tolerability of ONL1204 in Patients With Macula-off, Rhegmatogenous Retinal Detachment	Phase 1	Completed	Oct 21, 2019	Aug 24, 2021 (actual)
NCT05730218	A Phase 2 Study to Assess the Safety and Efficacy of Intravitreal ONL1204 Ophthalmic Solution in Subjects With Mac-off Retinal Detachment	2	Completed	Apr 4, 2023	Feb 21, 2024 (actual)